Physics / mechanism
Bioscaffolds fabricated via additive manufacturing provide a porous, three-dimensional substrate that mimics extracellular matrix architecture to support cell attachment, proliferation, and differentiation. Core techniques: extrusion-based bioprinting (fused deposition of thermoplastics or hydrogels, resolution ~100–500 µm), stereolithography/DLP (photopolymerisation, resolution ~25–50 µm), and inkjet/laser-assisted printing (~10–50 µm). Key parameters: pore geometry (50–500 µm for vascularisation), mechanical stiffness matched to target tissue (0.1–40 kPa for soft tissue, 10–1,000 MPa for bone), biocompatibility, and degradation kinetics. Material classes: PCL, PLGA, hydroxyapatite composites, GelMA, and decellularised ECM bioinks. Current SoA includes perfusable vascular networks and organoid-integrated scaffolds in research; clinical translation is thin, mainly orthopaedic and dental.
Competitive landscape
Primary competition comes from decellularised tissue matrices (superior biological complexity, poor reproducibility) and electrospun fibre meshes (sub-micron fibre diameter, limited 3D complexity). Hydrogel casting remains dominant for in-vitro assays. Emerging rival: organ-on-chip microfluidics, which bypasses scaffold geometry entirely for drug-screening applications.
Companies using
Connected ideas
Sources
Frontier (open questions)
- To be added.